Cargando…

Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms

BACKGROUND: Xihuang Pills/Capsules have a longstanding history of utilization in traditional Chinese medicine (TCM) for treating cancer. Nevertheless, a comprehensive investigation is required regarding the specific impacts and safety of Xihuang Pills/Capsules in individuals with uterine cervical ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huirong, Tian, Guangyu, Wu, Chunli, Sun, Xiaowen, Li, Kejian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470801/
https://www.ncbi.nlm.nih.gov/pubmed/37653807
http://dx.doi.org/10.1097/MD.0000000000034846
_version_ 1785099762977996800
author Xu, Huirong
Tian, Guangyu
Wu, Chunli
Sun, Xiaowen
Li, Kejian
author_facet Xu, Huirong
Tian, Guangyu
Wu, Chunli
Sun, Xiaowen
Li, Kejian
author_sort Xu, Huirong
collection PubMed
description BACKGROUND: Xihuang Pills/Capsules have a longstanding history of utilization in traditional Chinese medicine (TCM) for treating cancer. Nevertheless, a comprehensive investigation is required regarding the specific impacts and safety of Xihuang Pills/Capsules in individuals with uterine cervical neoplasms. Thus, conducting a meta-analysis is essential to evaluate the clinical effectiveness of combining Xihuang Pills/Capsules with Western medicine in patients with cervical neoplasms. METHODS: The research involved searching 5 English and 4 Chinese databases for randomized controlled trials (RCTs) investigating the use of Xihuang Pills/Capsules in conjunction with Western medicine for treating uterine cervical neoplasms. Subsequently, statistical analysis was carried out using Review Manager software (version 5.3). RESULTS: This research encompassed 10 RCTs involving 937 patients. The findings revealed that the combination of Xihuang Pills/Capsules with Western medicine treatment led to improvements in various aspects of the patients’ condition. Specifically, there was an enhancement in the short-term efficacy rate (risk ratio [RR] = 1.14, 95% confidence interval [CI]: 1.06–1.22, P = .0003), Karnofsky performance score (KPS) (mean difference [MD] = 5.90, 95% CI: 0.54–11.26, P = .03), survival rates, CD3+, CD3 + CD4+, CD3 + CD8+, CD3–CD56 + cells, and immunoglobulin M in patients with uterine cervical neoplasms. Moreover, the combination treatment resulted in a reduction of adverse reactions, including gastrointestinal reactions (RR = 0.52, 95% CI: 0.42–0.64, P < .00001), radiation proctitis (RR = 0.47, 95% CI: 0.33–0.68, P < .0001), myelosuppression (RR = 0.41, 95% CI: 0.26–0.64, P < .0001), as well as carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) levels. Additionally, the treatment exhibited an inhibitory effect on white blood cells (WBCs) and platelets (PLTs). CONCLUSION: The amalgamation of Xihuang Pills/Capsules with conventional anti-tumor therapy proves to be both effective and safe in the treatment of cervical neoplasms. However, further validation through high-quality RCTs is necessary to substantiate these findings.
format Online
Article
Text
id pubmed-10470801
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104708012023-09-01 Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms Xu, Huirong Tian, Guangyu Wu, Chunli Sun, Xiaowen Li, Kejian Medicine (Baltimore) 3800 BACKGROUND: Xihuang Pills/Capsules have a longstanding history of utilization in traditional Chinese medicine (TCM) for treating cancer. Nevertheless, a comprehensive investigation is required regarding the specific impacts and safety of Xihuang Pills/Capsules in individuals with uterine cervical neoplasms. Thus, conducting a meta-analysis is essential to evaluate the clinical effectiveness of combining Xihuang Pills/Capsules with Western medicine in patients with cervical neoplasms. METHODS: The research involved searching 5 English and 4 Chinese databases for randomized controlled trials (RCTs) investigating the use of Xihuang Pills/Capsules in conjunction with Western medicine for treating uterine cervical neoplasms. Subsequently, statistical analysis was carried out using Review Manager software (version 5.3). RESULTS: This research encompassed 10 RCTs involving 937 patients. The findings revealed that the combination of Xihuang Pills/Capsules with Western medicine treatment led to improvements in various aspects of the patients’ condition. Specifically, there was an enhancement in the short-term efficacy rate (risk ratio [RR] = 1.14, 95% confidence interval [CI]: 1.06–1.22, P = .0003), Karnofsky performance score (KPS) (mean difference [MD] = 5.90, 95% CI: 0.54–11.26, P = .03), survival rates, CD3+, CD3 + CD4+, CD3 + CD8+, CD3–CD56 + cells, and immunoglobulin M in patients with uterine cervical neoplasms. Moreover, the combination treatment resulted in a reduction of adverse reactions, including gastrointestinal reactions (RR = 0.52, 95% CI: 0.42–0.64, P < .00001), radiation proctitis (RR = 0.47, 95% CI: 0.33–0.68, P < .0001), myelosuppression (RR = 0.41, 95% CI: 0.26–0.64, P < .0001), as well as carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) levels. Additionally, the treatment exhibited an inhibitory effect on white blood cells (WBCs) and platelets (PLTs). CONCLUSION: The amalgamation of Xihuang Pills/Capsules with conventional anti-tumor therapy proves to be both effective and safe in the treatment of cervical neoplasms. However, further validation through high-quality RCTs is necessary to substantiate these findings. Lippincott Williams & Wilkins 2023-08-25 /pmc/articles/PMC10470801/ /pubmed/37653807 http://dx.doi.org/10.1097/MD.0000000000034846 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3800
Xu, Huirong
Tian, Guangyu
Wu, Chunli
Sun, Xiaowen
Li, Kejian
Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title_full Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title_fullStr Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title_full_unstemmed Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title_short Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms
title_sort meta-analysis of the efficacy and safety of xihuang pills/capsules in adjuvant treatment of uterine cervical neoplasms
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470801/
https://www.ncbi.nlm.nih.gov/pubmed/37653807
http://dx.doi.org/10.1097/MD.0000000000034846
work_keys_str_mv AT xuhuirong metaanalysisoftheefficacyandsafetyofxihuangpillscapsulesinadjuvanttreatmentofuterinecervicalneoplasms
AT tianguangyu metaanalysisoftheefficacyandsafetyofxihuangpillscapsulesinadjuvanttreatmentofuterinecervicalneoplasms
AT wuchunli metaanalysisoftheefficacyandsafetyofxihuangpillscapsulesinadjuvanttreatmentofuterinecervicalneoplasms
AT sunxiaowen metaanalysisoftheefficacyandsafetyofxihuangpillscapsulesinadjuvanttreatmentofuterinecervicalneoplasms
AT likejian metaanalysisoftheefficacyandsafetyofxihuangpillscapsulesinadjuvanttreatmentofuterinecervicalneoplasms